Clinical Trial: A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Thr

Brief Summary: The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis

Detailed Summary:
Sponsor: Lux Biosciences, Inc.

Current Primary Outcome: vitreous haze [ Time Frame: 16 and 24 weeks ]

Original Primary Outcome:

Current Secondary Outcome: BCVA [ Time Frame: 24 weeks ]

Original Secondary Outcome:

Information By: Lux Biosciences, Inc.

Dates:
Date Received: November 27, 2006
Date Started: January 2007
Date Completion:
Last Updated: October 9, 2012
Last Verified: October 2012